如何用BRAF抑制剂治疗难治/复发性毛细胞白血病
毛细胞白血病(HCL)对嘌呤类似物一线化疗反应良好,但约半数患者出现1次或多次复发并逐渐耐药。本文结合3例挑战性病例,阐述BRAF抑制剂(维莫非尼或达拉非尼)单用或与利妥昔单抗联合在临床试验及超说明书常规实践中的应用,并讨论其他在研方案。
要点
- 约半数HCL患者经历1次或多次复发,对嘌呤类似物逐渐耐药。
- BRAF-V600E抑制剂单用或与利妥昔单抗联合是吸引人的无化疗策略。
- 其他在研方案包括依鲁替尼抑制BTK及BRAF与MEK联合抑制。
核心结论
- BRAF抑制剂单用或与利妥昔单抗联合正在成为多种临床场景下吸引人的无化疗策略,包括有严重感染风险的患者及复发或难治性HCL患者。
研究设计与样本
- 本文为基于3例挑战性临床病例的经验总结,聚焦BRAF抑制剂在临床试验及常规实践超说明书使用中的经验。
主要发现
- 约半数患者经历1次或多次复发,且对嘌呤类似物逐渐耐药。
- 口服特异性BRAF-V600E抑制剂(维莫非尼或达拉非尼)消除HCL特有的形态学、表型及分子特征及其典型抗凋亡行为。
- BRAF抑制剂与利妥昔单抗联合在复发或难治性HCL中高度有效。
- 其他在研治疗包括依鲁替尼抑制BTK及达拉非尼或维莫非尼联合曲美替尼或考比替尼抑制BRAF与MEK。
临床怎么用
- 进展时标准治疗选择包括第二疗程嘌呤类似物单用或联合利妥昔单抗,第二次复发时使用抗CD22免疫毒素moxetumomab pasudotox。
- BRAF抑制剂可用于有严重感染或感染风险的患者,以及与利妥昔单抗联合用于复发或难治性HCL患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, approximately half of patients experience 1 or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive agents. At progression, standard therapeutic options include a second course of purine analogs alone or in combination with rituximab and, upon second relapse, therapy with the anti-CD22 immunotoxin moxetumomab pasudotox. Furthermore, blockade of the mutant BRAF-V600E kinase (the pathogenetic hallmark of HCL) through orally available specific inhibitors (vemurafenib or dabrafenib) effaces the peculiar morphologic, phenotypic, and molecular identity of this disease and its typical antiapoptotic behavior and is emerging as an attractive chemotherapy-free strategy in various clinical scenarios. These include patients with, or at risk of, severe infections and, in a highly effective combination with rituximab, patients with relapsed or refractory HCL. Other treatments explored in clinical trials are BTK inhibition with ibrutinib and co-inhibition of BRAF (through dabrafenib or vemurafenib) and its downstream target MEK (through trametinib or cobimetinib). Here, we focus on our experience with BRAF inhibitors in clinical trials and as off-label use in routine practice by presenting 3 challenging clinical cases to illustrate their management in the context of all available treatment options.
引用
- Falini B, De Carolis L, Tiacci E, et al. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood. 2022. PMID: 35143639. doi:10.1182/blood.2021013502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。